drugset / Trial / NCT02409316
[18F]FES PET/CT in Endocrine Refractory Breast Cancer
NaSingle-groupOpen-labelDiagnostic
Summary
In this study, positron emission tomography (PET/CT) imaging will be used to evaluate estrogen receptor (ER) activity in sites of metastatic disease using the investigational radiotracer \[18F\]fluoroestradiol (FES).
Timeline
- Start
- 2015-10-15
- Primary completion
- 2025-08-01
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F-18 16 Alpha-Fluoroestradiol | Diagnostic / imaging agent | — | — |